Showing 21-30 of 30 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A prodrug system for targeted activation of small molecules in beta cells | The Brigham and Women’s Hospital, Inc. | Amit Choudhary | Cures | 01-February-2024 to 31-January-2027 | $2.250.000,00 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 30-June-2027 | $1.341.376,33 |
| Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D | Massachusetts General Hospital | Mark Poznansky | Cures | 01-April-2023 to 31-March-2026 | $777.168,00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2022 to 30-September-2025 | $12.998.645,40 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212.708,89 |
| Research and Data Research | T1D Exchange, Inc. | Jaime Lucove | Transportfolio | 01-December-2022 to 30-November-2025 | $620.435,07 |
| The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O'Donnell | Improving Lives | 01-July-2023 to 30-June-2026 | $390.792,17 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8.913.450,00 |
| Evaluating the dose and toxicity of telaprevir in a rat model of T1D | Joslin Diabetes Center Inc. | Rohit Kulkarni | Cures | 01-June-2022 to 31-December-2025 | $494.000,00 |
| Advanced Oxygen Generator for Oxygenated Cell Capsules | Giner, Inc. | Linda Tempelman | Cures | 01-June-2021 to 30-September-2026 | $448.173,29 |